**METHOD FOR DETERMINING THE RISK OF DEVELOPING ALZHEIMER’S DISEASE**

The present invention relates to an *in vitro* method for determining the risk of developing Alzheimer’s disease or a cognitive disorder similar to said disease, an *in vitro* method for designing a personalized therapy in a subject suffering from mild cognitive impairment and an *in vitro* method for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer’s or a cognitive disorder similar to said disease based on determining, in a sample from the subject, the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant. The invention also relates to the use of E2F4 or a functionally equivalent variant thereof, wherein the E2F4 or variant is phosphorylated in threonine as a marker of the risk of developing Alzheimer’s disease or a cognitive disorder similar to Alzheimer’s disease. Finally, the invention relates to a kit comprising a reagent capable of determining the level of phosphorylation in threonine residues of E2F4 protein and the use of said kit.
Description

Field of the Invention

[0001] The present invention relates to methods for determining the risk of developing Alzheimer's disease and for designing a personalized therapy and for selecting patients.

Background of the Invention

[0002] Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders in Western societies. To date, there are no known therapies that stop this condition, and most clinical trials which have been designed to date aimed at inhibiting beta-amyloid peptide or hyperphosphorylated tau protein production and/or activity. Due to the failure of the clinical trials conducted to date, particularly the failure to obtain any cognitive improvement after treatment with solanezumab and bapineuzumab antibodies, the need to move these treatments forward to early phases of the disease before the neurodegenerative process becomes irreversible has been considered.

[0003] This type of approach is being carried out today in patients with familial Alzheimer's, a rare form of Alzheimer's which is characterized by the existence of mutations accelerating the neurodegenerative process. Nevertheless, the highest percentage of patients suffers from sporadic Alzheimer's, a type of pathology which is not predictable as of today.

[0004] Biomarkers that have been described to date are mainly based on neuroimaging techniques (e.g., senile plaque density and atrophy quantification in different regions of the brain, brain glucose metabolism analysis) and techniques for the quantification of soluble beta-amyloid and tau forms in the cerebrospinal fluid or blood serum of patients (Kang et al., 2014 Korean J Physiol Pharmacol. 18: 447-456). All these techniques are therefore based on analyzing late products of the pathology.

[0005] There is therefore a need to identify non-invasive early markers of Alzheimer's which allow making the diagnosis in the earliest possible stage of the disease, and therefore determining the risk of developing Alzheimer's disease.

Brief Description of the Invention

[0006] In a first aspect, the invention relates to an in vitro method for determining the risk of developing Alzheimer's disease or a cognitive disorder similar to said disease in a subject, which method comprises:

a) determining in a sample from the subject the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant and
b) comparing the level of phosphorylation obtained in a) to a reference value,

wherein an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to a reference value is indicative that said subject has a high risk of developing Alzheimer's or a cognitive disorder similar to said disease.

[0007] In a second aspect, the invention relates to an in vitro method for designing a personalized therapy in a subject suffering from mild cognitive impairment, which method comprises

a) determining in a sample from the subject the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant and
b) comparing the level of phosphorylation obtained in a) to a reference value,

wherein an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to the reference value is indicative that said subject is susceptible to receive a therapy for the prevention and/or treatment of Alzheimer's disease or a cognitive disorder similar to said disease.

[0008] In a third aspect, the invention relates to an in vitro method for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer's or a cognitive disorder similar to said disease, which method comprises

a) determining in a sample from the subject the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant and
b) comparing the level of phosphorylation obtained in a) to a reference value,

wherein an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to the reference value is indicative that said subject is a candidate for receiving a therapy for the prevention and/or treatment of Alzheimer's disease or a cognitive disorder similar to said disease.

[0009] In a fourth aspect, the invention relates to the use of E2F4 or a functionally equivalent variant thereof, wherein the E2F4 or variant is phosphorylated in threonine as a marker of the risk of developing Alzheimer's disease or a cognitive disorder similar to Alzheimer's disease.

[0010] In a fifth aspect, the invention relates to a kit comprising a reagent capable of determining the level of phosphorylation in threonine residues of E2F4 protein for determining the risk of a subject developing Alzheimer's or a cognitive disorder similar to Alzheimer's disease, for designing a personalized therapy in a subject or for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer's disease or a cognitive disorder similar to Alzheimer's disease.
ease.

[0011] In a sixth aspect, the invention relates to the use of a kit according to the invention for determining the risk of a subject developing Alzheimer’s disease or a cognitive disorder similar to said disease in a subject, for designing a personalized therapy in a subject suffering from mild cognitive impairment or for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer’s or a cognitive disorder similar to said disease.

Brief Description of the Drawings

[0012]

Figure 1 shows levels of neuronal tetraploidy in human frontal and parietal cortex, estimated by means of flow cytometry in fresh cell nuclei that are positive for the neuron-specific NeuN antigen. An increase in the percentage of tetraploid neurons prior to the presence of neurofibrillary tangles, which are not detected in the neocortex until Braak Stages V-VI, the final stage of the pathology where the patients exhibit symptoms of AD, is observed. *p<0.05; **p<0.01; ***p<0.005 (Student’s t-test).

Figure 2 shows the ELISA quantification, in normalized arbitrary units, of the levels of E2F4 (E2F4) and E2F4 phosphorylated in Thr residues (pThr-E2F4) present in cerebral cortex extracts of 8-week old wild-type and APP/PS1 mice. *p<0.05 (Student’s t-test).

Figure 3 shows levels of neuronal tetraploidy in frontal and parietal cortex of control mice or APP/PS1 mice (APP/PS1) of the indicated ages, estimated by means of flow cytometry in fresh cell nuclei that are positive for the neuron-specific NeuN antigen. An increase in the percentage of tetraploid neurons in APP/PS1 mice at 2 months of age, prior to the presence of β-amyloid plaques, is observed (Zhang et al., 2012 Neurobiol. Aging 33, 2681-2677). *p<0.05; ***p<0.005 (Student’s t-test).

Methods of the invention

[0014] In a first aspect, the invention relates to an in vitro method for determining the risk of developing Alzheimer’s disease or a cognitive disorder similar to said disease in a subject (first method of the invention), which method comprises

a) determining in a sample from the subject the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant and
b) comparing the level of phosphorylation obtained in a) to a reference value,

wherein an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to a reference value is indicative that said subject has a high risk of developing Alzheimer’s or a cognitive disorder similar to said disease.

[0015] In a particular embodiment, the subject suffers from mild cognitive impairment.

[0016] As it is used herein, “mild cognitive impairment”, also known as incipient dementia or isolated cognitive impairment, refers to a nosologic entity that seeks to describe the symptomatology before the onset of dementia. Affected individuals suffer from impairments that are more advanced than expected for their age and level of education, but these impairments do not significantly interfere with their daily activities. It is considered as the limit between normal aging and dementia.

[0017] The person skilled in the art is capable of identifying if a subject has a mild cognitive impairment based, for example, on the diagnostic criteria set forth in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and in the International Classification of Diseases, which allow physicians to make their diagnoses.

[0018] In a particular embodiment of the first method of the invention, the subject is a human and the neurodegenerative disease is Alzheimer’s disease, or the subject is a dog and the cognitive disorder similar to Alzheimer’s disease is cognitive dysfunction syndrome.

[0019] As it is used herein, the expression “risk of developing Alzheimer’s disease or a cognitive disorder similar to said disease” refers to the predisposition, susceptibility, propensity or likelihood of a subject developing Alzheimer’s disease or a cognitive disorder similar to said disease. The risk of developing a neurodegenerative disease, Alzheimer’s disease or a cognitive disorder similar to said disease generally means that there is a high or low risk or a higher or lower risk. Therefore, a subject with a high risk of developing Alzheimer’s disease or a cognitive disorder similar to said disease has a likelihood of developing said disease of at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 97%, or at least 98%, or at least 99%, or at least 100%. Similarly, a subject with a low risk of developing Alzheimer’s disease or a cognitive
disorder similar to said disease is a subject having at least a likelihood of developing said disease of at least 0%, or at least 1%, or at least 2%, or at least 3%, or at least 5%, or at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 49%.

[0020] In general, the expression "predicting the risk", "prediction of the risk" or the like, refers to the risk of a patient developing Alzheimer's disease or a cognitive disorder similar to said disease, whether it is high or low. As will be understood by those skilled in the art, although the prediction (or risk) is preferable, it does not have to be correct for all the subjects to be evaluated, although it is preferable for it to be so. The term, however, requires a statistically significant part of the subjects being identified as exhibiting a higher likelihood of having a specific result. The person skilled in the art can determine without much difficulty if a part is statistically significant using different, well-known statistical evaluation tools, for example, the determination of confidence intervals, determination of p-value, cross-validation with classification indices, etc. Preferred confidence intervals are at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95%, p-values are preferably 0.1, 0.05, 0.02, 0.01 or less.

[0021] The term "Alzheimer's disease or AD" refers to a mental impairment associated with a specific degenerative brain disease which is characterized by the appearance of senile plaques, neurofibrillary tangles and progressive neuronal loss clinically manifested as progressive memory deficiencies, confusion, behavioral problems, inability to take care of oneself, gradual physical deterioration, and ultimately death. In preferred embodiments, Alzheimer's disease is a disease in any of the stages according to the Braak scale:

- Stages I-II: the brain area affected by the presence of neurofibrillary tangles corresponds to the transentorhinal region of the brain
- Stages III-IV: the affected brain area also extends to areas of the limbic region, such as the hippocampus
- Stages V-VI: the affected brain area also involves the neocortical region.

[0022] This classification by neuropathological stages is correlated with the clinical progression of the disease, there being parallelism between memory decline with neurofibrillary changes and the formation of neuritic plaques in the entorhinal cortex and hippocampus (stages I to IV). Likewise, the isocortical presence of these changes (stages V and VI) is correlated with clinically severe alterations. The transentorhinal stage (I-II) corresponds to clinically silent periods of the disease. The limbic stage (III-IV) corresponds to a clinically incipient AD. The neocortical stage corresponds to a fully developed AD.

[0023] As it is used herein, "cognitive dysfunction syndrome or SDC" refers to a syndrome that any pet can have and corresponds to a state of dementia in which the cognitive process is compromised, which can occur with motor or sensorial symptomatology or veterinary problems. Cognitive dysfunction syndrome (CDS) in dogs is an age-associated neurodegenerative disorder which is characterized by a decline in brain functions. Like Alzheimer's disease, extracellular beta-amyloid (PBA) protein deposits, but not intracellular tau protein deposits, are produced. This PBA deposit is the final result of extreme oxidative stress and greater formation of insoluble forms of PBA 1-42, which are determined by genetic and environmental interaction.

[0024] In a second aspect, the invention relates to an in vitro method for designing a personalized therapy in a subject suffering from mild cognitive impairment (second method of the invention), which method comprises

a) determining in a sample from the subject the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant and
b) comparing the level of phosphorylation obtained in a) to a reference value,

wherein an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to the reference value is indicative that said subject is susceptible to receive a therapy for the prevention and/or treatment of Alzheimer's disease or a cognitive disorder similar to said disease.

[0025] In a particular embodiment of the second method of the invention, the subject is a human and the therapy is for the prevention and/or treatment of Alzheimer's disease, or the subject is a dog and the therapy is for the prevention and/or treatment of cognitive dysfunction syndrome.

[0026] As it is used herein, the term "preventive therapy" refers to the prevention of or a set of prophylactic measures for preventing a disease to prevent or delay the onset of the symptomatology of the disease. Particularly, said term refers to the prevention of or the set of measures for preventing the onset or delaying the clinical symptomatology associated with Alzheimer's disease or a cognitive disorder similar to said disease. Desired clinical results associated with the administration of said treatment to a subject include, but are not limited to, stabilizing the pathological state of the disease, delaying the progression of the disease or improving the physiological state of the subject.

[0027] As it is used herein, "therapy for the treatment" refers to the tentative recovery of a health issue, generally after a diagnosis, specifically of Alzheimer's disease or a cognitive disorder similar to said disease. So it is not necessarily a cure, i.e., a complete reversion of a disease. Therefore, as it is used herein "treatment" covers any treatment of a disease, a disorder or a condition of a mammal, particularly a human being, and includes inhibiting the disease or condition, i.e., caus-
ing the regression of the disease or condition or improving one or more symptoms of the disease or condition. The population of subjects treated by means of the method includes a subject suffering from the unwanted condition or disease, as well as subjects at risk of developing the condition or disease. Therefore, a person skilled in the art understands that a treatment can improve the condition of the patient, but it may not be a complete cure for the disease.

[0028] Preventive or curative treatments suitable in Alzheimer’s disease or in a cognitive disorder similar to said disease include, but are not limited to, choline-esterase inhibitors such as, for example, donepezil hydrochloride (Aricept), rivastigmine (Exelon) and galantamine (Reminyl), N-methyl D-aspartate (NMDA) receptor antagonists, or monoclonal antibodies such as solanezumab and bapineuzumab.

[0029] In a third aspect, the invention relates to an in vitro method for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer’s or a cognitive disorder similar to said disease (third method of the invention), which method comprises

a) determining in a sample from the subject the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant and
b) comparing the level of phosphorylation obtained in a) to a reference value,

wherein an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to the reference value is indicative that said subject is a candidate for receiving a therapy for the prevention and/or treatment of Alzheimer’s disease or a cognitive disorder similar to said disease.

[0030] As it is used herein, the term “select” refers to the action of choosing a subject to put said subject under a preventive or curative treatment for Alzheimer’s disease or a cognitive disorder similar to said disease.

[0031] In a particular embodiment of the third method of the invention, the subject is a human and the therapy is for the prevention and/or treatment of Alzheimer’s disease, or the subject is a dog and the therapy is for the prevention and/or treatment of cognitive dysfunction syndrome.

[0032] The first, second and third methods of the invention comprise in a first step determining in a sample from a subject the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant.

[0033] As it is used herein, “sample” refers to the biological material isolated from a subject. The sample can be isolated from any suitable biological fluid or tissue including, by way of illustrative and non-limiting example, cerebrospinal fluid, blood serum, blood plasma, tears, sweat, saliva, urine and feces.

[0034] In a particular embodiment of the methods of the invention, the sample is selected from the group consisting of cerebrospinal fluid, blood serum, blood plasma, blood and peripheral blood mononuclear cells.

[0035] As it is used herein, the term “subject” refers to a member of a mammalian animal species and includes, but is not limited to, domestic animals, primates and humans. In a particular embodiment, the subject is preferably a male or female human being of any age or race. In another particular embodiment, the subject is a dog. In a more particular embodiment, the subject suffers from mild cognitive impairment.

[0036] Human “E2F4” protein corresponds with the protein identified in the Uniprot database as Q16254 (27 May 2015). E2F4 protein in dogs corresponds with the protein identified in the Uniprot database as J9NSJ4 (27 May 2015) and the isoform thereof identified in the Uniprot database as F1P6YO (1 April 2015).

[0037] In the context of the present invention, the term “functionally equivalent variant of E2F4 protein” includes (i) variants of E2F4 protein in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue), wherein such substituted amino acid residue may or may not be a residue encoded by the genetic code, as well as (ii) variants comprising an insertion or a deletion of one or more amino acids and playing the same function as E2F4 protein, i.e., capable of inhibiting the expression of genes, specifically genes involved in DNA replication and cell cycle regulation.

[0038] The variants according to the invention preferably have a sequence identity with the E2F4 amino acid sequence of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%. The degree of identity between the variants and the specific sequences of E2F4 protein defined above can be determined using algorithms and computational methods that are well-known for those skilled in the art. The identity between two amino acid sequences is preferably determined using the BLASTP algorithm [BLAST Manual, Altschul, S., et. al., NCBI NLM NIH Bethesda, Md. 20894, Altschul, S., et. al., J. Mol. Biol. 215: 403-410 (1990)].

[0039] The degree of phosphorylation of a protein can be determined using any conventional method known by those skilled in the art. Various assays are known for determining the state of phosphorylation of a protein, or the amino acid residue which is phosphorylated in a specific protein, such as, for example, in vitro kinase activity assays using radioactively labeled ATP; two-dimensional electrophoresis of proteins thus phosphorylated and labeled (which allows analyzing how many amino acid residues are phosphorylated in a protein); mass spectrometry of the previously purified protein the state of phosphorylation of which is to be measured; directed mutagenesis followed by the in vitro kinase activity assay with the purified proteins; phosphopeptide analysis which in-
volves separating a phosphorylated protein into two dimensions after trypsin digestion, or the less technically complicated Western blot, which contemplates using antibodies against said protein specifically recognizing the amino acid residue or epitope of the protein which is phosphorylated. Techniques for detecting phosphorylated residues in proteins are well-known by the person skilled in the art and are described in the state of the art. Alternatively, E2F4 protein can be immunoprecipitated and the total level of phosphorylation in threonines or in the threonine residues of interest can be determined by means of Western Blot.

[0040] In a preferred embodiment, the determination of the phosphorylation is carried out by means of the ELISA technique.

[0041] The immunoassay known as ELISA is based on the use of enzyme-labeled antibodies or antigens, such that the conjugates formed between the target antigen and the labeled antibody results in the formation of enzymatically active complexes. Due to the fact that one of the components (the labeled antibody or antigen) is immobilized on a support, the antibody-antigen complexes are immobilized on the support and can therefore be detected by the addition of a substrate which is converted by the enzyme into a product that is detectable by spectrophotometry or fluorometry, for example. Preferably, the ELISA assay used in the methods of the present invention is a sandwich ELISA assay, wherein a first antibody (capture antibody) which is adsorbed on a solid support and is specific for the antigen to be detected, which would allow capturing the antigen to be detected on said support, is used. The sandwich ELISA assay requires using a second antibody (detection antibody) which is also specific for the antigen to be detected and is added to the previously formed complexes between the antigen and the capture antibody.

[0042] As it is used herein, the term "antibody" seeks to include both chimeric or recombinant antibodies and monoclonal antibodies and polyclonal antibodies or proteolytic fragments thereof, such as Fab or F(ab')2 fragments, etc. Furthermore, the DNA encoding the variable region of the antibody can be inserted in other antibodies to thereby produce chimeric antibodies. Single-chain antibodies (scFv) can be polypeptides formed by single chains having the characteristic capacity of an antigen-binding antibody and comprising a pair of amino acid sequences homologous or analogous to the variables regions of the light and heavy chains of immunoglobulins (VH-VL or scFv binding). Polypeptides analogous to the variable regions of the light and heavy chains of an antibody can bind, if desired, through a binding polypeptide. Methods for producing antibodies are well-known and described in the state of the art.

[0043] As will be understood by the person skilled in the art, given that the level of phosphorylation in threonine residues of E2F4 protein or a functionally equivalent variant is to be determined, the ELISA assay can be carried out by means of a sandwich-type ELISA assay, wherein the capture antibody is an antibody specific against E2F4 protein, and wherein the detection antibody is an antibody specific against phosphothreonine or against specific phosphothreonine residues present in E2F4 protein. Alternatively, a sandwich ELISA assay can be carried out using an anti-phosphothreonine antibody or an antibody specific against one or more specific phosphothreonine residues as a capture antibody, for the purpose of immobilizing all those proteins with phosphorylation in phosphothreonine residues, and an anti-E2F4 antibody as a detection antibody.

[0044] As will be understood by the person skilled in the art, given that the level of phosphorylation in threonine residues of E2F4 protein or a functionally equivalent variant is to be determined, it is recommendable to quantify the overall levels of E2F4 protein such that the values of E2F4 phosphorylated in threonine can be normalized. The levels of E2F4 can be determined, for example, by means using an antibody recognizing E2F4, such as those commercially available antibodies. Additionally, given that the level of phosphorylation of E2F4 protein is to be determined, it is recommendable to include phosphatase inhibitors in the assays, such that the levels of phosphorylation are not altered.

[0045] In a particular embodiment of the methods of the invention, the first step comprises determining the phosphorylation of the threonine residue selected from the group consisting of the threonine residue in position 248 (Thr248), threonine residue in position 250 (Thr250), threonine residue in position 14 (Thr14), threonine residue in position 163 (Thr163), threonine residue in position 224 (Thr224) and threonine residue in position 333 (Thr333), and combinations thereof, of human E2F4 protein, or in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0046] As it is used herein, the term "positionally equivalent" refers to the position of an amino acid of an E2F4 protein which, by means of multiple amino acid sequence alignment of E2F4 protein, corresponds to Thr248, Thr250, Thr14, Thr163, Thr224 and/or Thr333 of human E2F4 protein.

[0047] Multiple sequence alignment can be carried out by means of the algorithm implemented in the CLUSTALW2 program (using standard parameters (alignment type: slow; matrix: Gnomon; gap open: 10; gap extension: 0.1; KTUP: 1; Window length: 5; Score type: percent; Top Diags: 5 and Pair Gap: 3). In another embodiment, multiple sequence alignment can be carried out by means of the algorithm implemented in the CLUSTAL OMEGA program using standard parameters (HAlign algorithm with default parameters and the default transition matrix is Gnomon, with a 6-bit gap opening penalty and a 1-bit gap extension).

[0048] In another more particular embodiment, the methods of the invention comprise determining the phosphorylation of one or more threonine residues of human
E2F4 protein, namely Thr248, Thr250, Thr14, Thr163, Thr224 and/or Thr333, or in one or more phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0049] In a more particular embodiment, the methods of the invention comprise determining the phosphorylation of only one of the threonine residues selected from the group consisting of Thr248, Thr250, Thr14, Thr163, Thr224 and Thr333 of human E2F4 protein, or in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0050] In another embodiment, the methods of the invention comprise determining the phosphorylation of two threonine residues selected from the group consisting of Thr248 and Thr250; Thr248 and Thr14; Thr248 and Thr163; Thr248 and Thr224; Thr248 and Thr333; Thr250 and Thr248; Thr250 and Thr14; Thr250 and Thr163; Thr250 and Thr224; Thr250 and Thr333; Thr14 and Thr163; Thr14 and Thr224; Thr14 and Thr333; Thr163 and Thr224; Thr163 and Thr333; and Thr224 and Thr333 of human E2F4 protein, or in two phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0051] In another embodiment, the methods of the invention comprise determining the phosphorylation of three threonine residues selected from the group consisting of Thr248, Thr250 and Thr14; Thr248, Thr250 and Thr163; Thr248, Thr250 and Thr224; Thr248, Thr250 and Thr333; Thr248, Thr14 and Thr163; Thr248, Thr14 and Thr224; Thr248, Thr14 and Thr333; Thr248, Thr163 and Thr224; Thr248, Thr163 and Thr333; Thr248, Thr224 and Thr333; Thr250 and Thr14; Thr250 and Thr163; Thr250 and Thr224; Thr250 and Thr333; Thr250 and Thr14; Thr250 and Thr163; Thr250 and Thr224; Thr250 and Thr333; Thr250 and Thr14; Thr250 and Thr163; Thr250 and Thr224; Thr250 and Thr333; Thr250 and Thr14; Thr250 and Thr163; Thr250 and Thr224; Thr250 and Thr333; Thr250 and Thr14; Thr250 and Thr163; Thr250 and Thr224; Thr250 and Thr333; Thr250 and Thr14; Thr250 and Thr163; Thr250 and Thr224; Thr250 and Thr333; Thr250 and Thr14; Thr250 and Thr163; Thr250 and Thr224; Thr250 and Thr333; and Thr224 and Thr333; and Thr14, Thr163, Thr224 and Thr333 of human E2F4 protein, or in four phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0053] In another embodiment, the methods of the invention comprise determining the phosphorylation of five threonine residues selected from the group consisting of Thr248, Thr250, Thr14, Thr163 and Thr224; Thr248, Thr250, Thr14, Thr163 and Thr333; Thr248, Thr250, Thr14, Thr163 and Thr333; Thr248, Thr250, Thr14, Thr163 and Thr333; Thr248, Thr250, Thr14, Thr163 and Thr333; and Thr250, Thr14, Thr163, Thr224 and Thr333 of human E2F4 protein, or in five phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0054] In another embodiment, the methods of the invention comprise determining the phosphorylation of six threonine residues, namely Thr248, Thr250, Thr14, Thr163, Thr224 and Thr333 of human E2F4 protein, or in six phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0055] In another embodiment, the methods of the invention comprise determining the phosphorylation in threonine of human E2F4 protein as detected by means of using anti-phosphothreonine antibodies.

[0056] In another embodiment, the methods of the invention comprise determining the mean phosphorylation in threonine residues of human E2F4 protein. By way of illustration, this determination can be carried out by means of isolating human E2F4, for example, by means of using human anti-E2F4 antibodies, followed by quantitative or semi-quantitative immunodetection using antibodies specific against phosphothreonine to that end.

[0057] In a particular embodiment of the methods of the invention, the subject is a dog and phosphorylation is determined for the threonine residue selected from the group consisting of threonine in position 311 (Thr311), threonine in position 313 (Thr313), threonine in position 76 (Thr76), threonine in position 225 (Thr225), threonine in position 286 (Thr286), threonine in position 391 (Thr391), threonine in position 40 (Thr40) and combinations thereof of dog E2F4 protein with Uniprot database accession number J9NSJ4, or in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0058] In another more particular embodiment, the methods of the invention comprise determining phosphorylation of one or more threonine residues of dog E2F4 protein with Uniprot database accession number J9NSJ4, namely Thr311, Thr313, Thr76, Thr225, Thr286, Thr391 and Thr40, or in one or more phosphorylatable, positionally equivalent amino acid residues of
another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0059] In a more particular embodiment, the methods of the invention comprise determining the phosphorylation of only one of the threonine residues selected from the group consisting of Thr311, Thr313, Thr76, Thr225, Thr286, Thr391 and Thr40 of dog E2F4 with Uniprot database accession number J9NSJ4, or in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0060] In another embodiment, the methods of the invention comprise determining the phosphorylation of two threonine residues selected from the group consisting of Thr311 and Thr313; Thr311 and Thr76; Thr311 and Thr225; Thr311 and Thr286; Thr311 and Thr391; Thr311 and Thr40; Thr313 and Thr76; Thr313 and Thr225; Thr313 and Thr286; Thr313 and Thr391; Thr313 and Thr40; Thr76 and Thr225; Thr76 and Thr286; Thr76 and Thr391; Thr76 and Thr40; Thr225 and Thr286; Thr225 and Thr391; Thr225 and Thr40; Thr286 and Thr391; Thr286 and Thr40; and Thr391 and Thr40 of dog E2F4 protein with Uniprot database accession number J9NSJ4, or in two phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0061] In another embodiment, the methods of the invention comprise determining the phosphorylation of three threonine residues selected from the group consisting of Thr311, Thr313 and Thr76; Thr311, Thr313 and Thr225; Thr311, Thr313 and Thr286; Thr311, Thr313 and Thr391; Thr311, Thr313 and Thr40; Thr311, Thr76 and Thr225; Thr311, Thr76 and Thr286; Thr311, Thr76 and Thr391; Thr311, Thr76 and Thr40; Thr311, Thr225 and Thr286; Thr311, Thr225 and Thr391; Thr311, Thr225 and Thr40; Thr311, Thr286 and Thr391; Thr311, Thr286 and Thr40; Thr311, Thr391 and Thr40; Thr311, Thr391 and Thr40; Thr311, Thr76 and Thr225; Thr311, Thr76 and Thr286; Thr311, Thr76 and Thr391; Thr311, Thr76 and Thr40; Thr311, Thr225 and Thr286; Thr311, Thr225 and Thr391; Thr311, Thr225 and Thr40; Thr311, Thr286 and Thr391; Thr311, Thr286 and Thr40; Thr311, Thr391 and Thr40; Thr311, Thr391 and Thr40; Thr311, Thr76 and Thr225; Thr311, Thr76 and Thr286; Thr311, Thr76 and Thr391; Thr311, Thr76 and Thr40; Thr311, Thr225 and Thr286; Thr311, Thr225 and Thr391; Thr311, Thr225 and Thr40; Thr311, Thr286 and Thr391; Thr311, Thr286 and Thr40; Thr311, Thr391 and Thr40; Thr311, Thr391 and Thr40; Thr311, Thr76 and Thr225; Thr311, Thr76 and Thr286; Thr311, Thr76 and Thr391; Thr311, Thr76 and Thr40; Thr311, Thr225 and Thr286; Thr311, Thr225 and Thr391; Thr311, Thr225 and Thr40; Thr311, Thr286 and Thr391; Thr311, Thr286 and Thr40; Thr311, Thr391 and Thr40; Thr311, Thr391 and Thr40; Thr311, Thr76 and Thr225; Thr311, Thr76 and Thr286; Thr311, Thr76 and Thr391; Thr311, Thr76 and Thr40; Thr311, Thr225 and Thr286; Thr311, Thr225 and Thr391; Thr311, Thr225 and Thr40; Thr311, Thr286 and Thr391; Thr311, Thr286 and Thr40; Thr311, Thr391 and Thr40; and Thr391 and Thr40 of dog E2F4 protein with Uniprot database accession number J9NSJ4, or in three phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0062] In another embodiment, the methods of the invention comprise determining the phosphorylation of four threonine residues selected from the group consisting of Thr311, Thr313, Thr76 and Thr225; Thr311, Thr313, Thr76 and Thr225; Thr311, Thr313, Thr76 and Thr286; Thr311, Thr313, Thr76 and Thr391; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; Thr311, Thr313, Thr76 and Thr40; and Thr311, Thr313, Thr76 and Thr40 of dog E2F4 protein with Uniprot database accession number J9NSJ4, or in four phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0063] In another embodiment, the methods of the invention comprise determining the phosphorylation of five threonine residues selected from the group consisting of Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; Thr311, Thr313, Thr76, Thr225 and Thr286; and Thr311, Thr313, Thr76, Thr225 and Thr286 of dog E2F4 protein with Uniprot database accession number J9NSJ4, or in five phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0064] In another embodiment, the methods of the invention comprise determining the phosphorylation of six threonine residues selected from the group consisting of Thr311, Thr313, Thr76, Thr225, Thr286 and Thr391;
Thr311, Thr313, Thr76, Thr225, Thr286 and Thr40; Thr311, Thr313, Thr76, Thr225, Thr391 and Thr40; Thr311, Thr313, Thr76, Thr286, Thr391 and Thr40; Thr311, Thr313, Thr225, Thr286, Thr391 and Thr40; Thr311, Thr313, Thr76, Thr225, Thr286, Thr391 and Thr40; and Thr313, Thr76, Thr225, Thr286, Thr391 and Thr40 of dog E2F4 protein with Uniprot database accession number J9NSJ4, or in six phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0065] In another embodiment, the methods of the invention comprise determining the phosphorylation of seven threonine residues, namely Thr311, Thr313, Thr76, Thr225, Thr286, Thr391 and Thr40 of dog E2F4 protein with Uniprot database accession number J9NSJ4, or in seven phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0066] In another particular embodiment of the methods of the invention, the subject is a dog and phosphorylation is determined for the threonine residue selected from the group consisting of positions 251 (Thr251), 253 (Thr253), 14 (Thr14), 165 (Thr165), 226 (Thr226), 332 (Thr332) and 241 (Thr241), and combinations thereof, of dog E2F4 protein with Uniprot database accession number F1P6Y0, or in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0067] In a more particular embodiment, the methods of the invention comprise determining the phosphorylation of only one of the threonine residues selected from the group consisting of Thr251, Thr253, Thr14, Thr165, Thr226, Thr332 and Thr241 of dog E2F4 protein with Uniprot database accession number F1P6Y0, or in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0068] In another embodiment, the methods of the invention comprise determining the phosphorylation of two threonine residues selected from the group consisting of Thr251 and Thr253; Thr251 and Thr14; Thr251 and Thr165; Thr251 and Thr226; Thr251 and Thr332; Thr251 and Thr241; Thr253 and Thr14; Thr253 and Thr165; Thr253 and Thr226; Thr253 and Thr332; Thr253 and Thr241; Thr14 and Thr165; Thr14 and Thr226; Thr14 and Thr332; Thr14 and Thr241; Thr165 and Thr226; Thr165 and Thr332; Thr165 and Thr241; and Thr226 and Thr332 and Thr241 of dog E2F4 protein with Uniprot database accession number F1P6Y0, or in two phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0069] In another embodiment, the methods of the invention comprise determining the phosphorylation of three threonine residues selected from the group consisting of Thr251, Thr253 and Thr14; Thr251, Thr253 and Thr165; Thr251, Thr253 and Thr226; Thr251, Thr253 and Thr332; Thr251, Thr253 and Thr241; Thr251, Thr14 and Thr165; Thr251, Thr14 and Thr226; Thr251, Thr14 and Thr332; Thr251, Thr14 and Thr241; Thr251, Thr165 and Thr226; Thr251, Thr165 and Thr332; Thr251, Thr165 and Thr241; Thr251, Thr226 and Thr332; Thr251, Thr226 and Thr241; Thr251, Thr332 and Thr241; Thr253, Thr14 and Thr165; Thr253, Thr14 and Thr226; Thr253, Thr14 and Thr332; Thr253, Thr14 and Thr241; Thr253, Thr165 and Thr226; Thr253, Thr165 and Thr332; Thr253, Thr165 and Thr241; Thr253, Thr226 and Thr332; Thr253, Thr226 and Thr241; Thr253, Thr332 and Thr241; Thr253, Thr14 and Thr165; Thr253, Thr14 and Thr226; Thr253, Thr14 and Thr332; Thr253, Thr14 and Thr241; Thr253, Thr165 and Thr226; Thr253, Thr165 and Thr332; Thr253, Thr165 and Thr241; and Thr253, Thr332 and Thr241 of dog E2F4 protein with Uniprot database accession number F1P6Y0, or in four phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0070] In another embodiment, the methods of the invention comprise determining the phosphorylation of four threonine residues selected from the group consisting of Thr251, Thr253, Thr14 and Thr165; Thr251, Thr253, Thr14 and Thr226; Thr251, Thr253, Thr14 and Thr332; Thr251, Thr253, Thr14 and Thr241; Thr251, Thr253, Thr165 and Thr226; Thr251, Thr253, Thr165 and Thr332; Thr251, Thr253, Thr165 and Thr241; Thr251, Thr253, Thr332 and Thr241; Thr251, Thr253, Thr241; Thr251, Thr332 and Thr241; Thr251, Thr14 and Thr165; Thr251, Thr14 and Thr226; Thr251, Thr14 and Thr332; Thr251, Thr14 and Thr241; Thr251, Thr165 and Thr226; Thr251, Thr165 and Thr332; Thr251, Thr165 and Thr241; Thr251, Thr226 and Thr332; Thr251, Thr226 and Thr241; Thr251, Thr332 and Thr241; Thr253, Thr14 and Thr165; Thr253, Thr14 and Thr226; Thr253, Thr14 and Thr332; Thr253, Thr14 and Thr241; Thr253, Thr165 and Thr226; Thr253, Thr165 and Thr332; Thr253, Thr165 and Thr241; and Thr253, Thr332 and Thr241 of dog E2F4 protein with Uniprot database accession number F1P6Y0, or in three phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

[0071] In another embodiment, the methods of the invention comprise determining the phosphorylation of five threonine residues selected from the group consisting of Thr251, Thr253, Thr14 and Thr165; Thr251, Thr253, Thr14 and Thr226; Thr251, Thr253, Thr14 and Thr332; Thr251, Thr253, Thr14 and Thr241; Thr251, Thr253, Thr165 and Thr226; Thr251, Thr253, Thr165 and Thr332; Thr251, Thr253, Thr165 and Thr241; Thr251, Thr253, Thr332 and Thr241; Thr251, Thr253, Thr241; Thr251, Thr332 and Thr241; Thr251, Thr14 and Thr165; Thr251, Thr14 and Thr226; Thr251, Thr14 and Thr332; Thr251, Thr14 and Thr241; Thr251, Thr165 and Thr226; Thr251, Thr165 and Thr332; Thr251, Thr165 and Thr241; Thr251, Thr226 and Thr332; Thr251, Thr226 and Thr241; Thr251, Thr332 and Thr241; Thr253, Thr14 and Thr165; Thr253, Thr14 and Thr226; Thr253, Thr14 and Thr332; Thr253, Thr14 and Thr241; Thr253, Thr165 and Thr226; Thr253, Thr165 and Thr332; Thr253, Thr165 and Thr241; and Thr253, Thr332 and Thr241 of dog E2F4 protein with Uniprot database accession number F1P6Y0, or in four phosphorylatable, positionally equivalent amino acid residues of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.
vention comprise determining the phosphorylation of five threonine residues selected from the group consisting of Thr251, Thr253, Thr14, Thr165 and Thr226; Thr251, Thr253, Thr14, Thr165 and Thr332; Thr251, Thr253, Thr14, Thr165 and Thr241; Thr251, Thr253, Thr14, Thr332 and Thr241; Thr251, Thr253, Thr165, Thr226 and Thr332; Thr251, Thr253, Thr165, Thr226 and Thr241; Thr251, Thr253, Thr165, Thr226 and Thr241; Thr251, Thr253, Thr165, Thr226 and Thr241; [0075] In another embodiment, the methods of the invention comprise determining the phosphorylation in threonine of dog E2F4 protein as detected by means of using anti-phosphothreonine antibodies.

[0076] A second step of the methods of the invention comprises comparing the level of phosphorylation obtained in the first step of the methods with a reference value.

[0077] As it is used herein, the term "reference value" refers to predetermined criteria used as a reference for evaluating the values or data obtained from the samples collected from a subject. The reference value or reference level can be an absolute value, a relative value, a value having an upper or lower limit, a range of values, an average value, a median value, a mean value, or a value compared to a particular control or baseline value. A reference value can be based on a value of an individual sample such as, for example, a value obtained from a sample from the subject being analyzed, but at an earlier point in time. The reference value can be based on a large number of samples, such as a population of subjects of the matching chronological age group, or based on a pool of samples including or excluding the sample being analyzed. In a particular embodiment, the reference value for a phosphorylated amino acid residue in E2F4 protein is the level of phosphorylation of said residue of the protein in a sample from a subject or population of control subjects, i.e., those that do not exhibit any neurodegenerative disorder, specifically those that do not exhibit Alzheimer's disease or a cognitive disorder similar to said disease. Typical reference samples will generally be obtained from subjects who are clinically well documented.

[0078] After the second step of comparison and according to the first method of the invention, an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to a reference value is indicative that said subject has a high risk of developing Alzheimer's or a cognitive disorder similar to said disease.

[0079] According to the second method of the invention, an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to the reference value is indicative that said subject is susceptible to receive a therapy for the prevention and/or treatment of Alzheimer's disease or a cognitive disorder similar to said disease.

[0080] According to the third method of the invention, an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to the reference value is indicative that said subject is a candidate for receiving a therapy for the prevention and/or treatment of Alzheimer's disease or a cognitive disorder similar to said disease.

[0081] As it is used herein, "increase in the level of phosphorylation" refers to the fact that the level of phosphorylation in at least one threonine residue of E2F4 is
greater than a reference value. The levels of phosphorylation are considered greater than their reference value when they are greater by at least 1.5%, at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150% or more compared to the reference value.  

[0082] Likewise, in the context of the present invention the level of phosphorylation decreases when the level of phosphorylation in a sample is lower than a reference value. The levels of phosphorylation are considered lower than their reference value when they are lower by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150% or more compared to the reference value.  

Use as a risk marker  

[0083] In another aspect, the invention relates to the use of E2F4 or a functionally equivalent variant thereof, wherein the E2F4 or variant is phosphorylated in threonine as a marker of the risk of developing Alzheimer's disease or a cognitive disorder similar to Alzheimer's disease.  

[0084] In a particular embodiment, E2F4 is of human origin and is phosphorylated in the threonine selected from the group consisting of threonine in position 248 (Thr248), threonine in position 250 (Thr250), threonine in position 14 (Thr14), threonine in position 163 (Thr163), threonine in position 224 (Thr224), threonine in position 333 (Thr333) and combinations thereof, and the disease is Alzheimer's disease.  

[0085] In another particular embodiment, E2F4 is of human origin and is phosphorylated in one or more threonine residues of human E2F4 protein, namely Thr248, Thr250, Thr14, Thr163, Thr224 and/or Thr333, and the disease is Alzheimer's disease.  

[0086] In a more particular embodiment, E2F4 is of human origin and is phosphorylated in only one of the threonine residues selected from the group consisting of Thr248, Thr250, Thr14, Thr163, Thr224 and Thr333, and the disease is Alzheimer's disease.  

[0087] In another particular embodiment, E2F4 is of human origin and is phosphorylated in two threonine residues selected from the group consisting of Thr248 and Thr250; Thr248 and Thr14; Thr248 and Thr163; Thr248 and Thr224; Thr248 and Thr333; Thr250 and Thr14; Thr250 and Thr163; Thr250 and Thr224; Thr250 and Thr333; Thr14 and Thr163; Thr14 and Thr224; Thr14 and Thr333; Thr163 and Thr224; Thr163 and Thr333; and Thr224 and Thr333, and the disease is Alzheimer's disease.  

[0088] In another particular embodiment, E2F4 is of human origin and is phosphorylated in three threonine residues selected from the group consisting of Thr248, Thr250 and Thr14; Thr248, Thr250 and Thr163; Thr248, Thr250 and Thr224; Thr248, Thr250 and Thr333; Thr248, Thr14 and Thr163; Thr248, Thr14 and Thr224; Thr248, Thr14 and Thr333; Thr248, Thr163 and Thr224; Thr248, Thr163 and Thr333; Thr248, Thr224 and Thr333; Thr250, Thr14 and Thr163; Thr250, Thr14 and Thr224; Thr250, Thr14 and Thr333; Thr250, Thr163 and Thr224; Thr250, Thr163 and Thr333; Thr250, Thr224 and Thr333; Thr250, Thr14 and Thr163; Thr248, Thr14 and Thr224; Thr248, Thr14 and Thr333; and Thr163, Thr224 and Thr333, and the disease is Alzheimer's disease.  

[0089] In another particular embodiment, E2F4 is of human origin and is phosphorylated in four threonine residues selected from the group consisting of Thr248, Thr250, Thr14 and Thr163; Thr248, Thr250, Thr14 and Thr224; Thr248, Thr250, Thr14 and Thr333; Thr248, Thr250, Thr163 and Thr224; Thr248, Thr250, Thr163 and Thr333; Thr248, Thr250, Thr224 and Thr333; Thr248, Thr14, Thr163 and Thr224; Thr248, Thr14, Thr163 and Thr333; Thr248, Thr14, Thr224 and Thr333; Thr248, Thr163, Thr224 and Thr333; Thr250, Thr14, Thr163 and Thr224; Thr250, Thr14, Thr163 and Thr333; Thr250, Thr14, Thr224 and Thr333; Thr250, Thr163, Thr224 and Thr333; and Thr14, Thr163, Thr224 and Thr333, and the disease is Alzheimer's disease.  

[0090] In another particular embodiment, E2F4 is of human origin and is phosphorylated in five threonine residues selected from the group consisting of Thr248, Thr250, Thr14, Thr163 and Thr224; Thr248, Thr250, Thr14, Thr163 and Thr333; Thr248, Thr250, Thr14, Thr224 and Thr333; Thr248, Thr250, Thr163 and Thr224; Thr248, Thr250, Thr163 and Thr333; Thr248, Thr14, Thr163, Thr224 and Thr333; and Thr14, Thr163, Thr224 and Thr333, and the disease is Alzheimer's disease.  

[0091] In another particular embodiment, E2F4 is of human origin and is phosphorylated in six threonine residues, namely Thr248, Thr250, Thr14, Thr163, Thr224 and Thr333 of human E2F4 protein, and the disease is Alzheimer's disease.  

[0092] In another embodiment of the use of E2F4 or a functionally equivalent variant thereof, wherein the E2F4 or variant is phosphorylated in threonine as a marker of the risk of developing Alzheimer's disease or a cognitive disorder similar to Alzheimer's disease, the E2F4 is dog E2F4 with Uniprot database accession number J9NSJ4 and is phosphorylated in the threonine selected from the group consisting of threonine in position 311 (Thr311), threonine in position 313 (Thr313), threonine in position 76 (Thr76), threonine in position 225 (Thr225), threonine in position 286 (Thr286), threonine in position 391 (Thr391), threonine in position 40 (Thr40) and combinations thereof, and the cognitive disorder similar to Alzheimer's disease is cognitive dysfunction syndrome.  

[0093] In another more particular embodiment, the
E2F4 is dog E2F4 with Uniprot database accession number J9NSJ4 and is phosphorylated in one, two, three, four, five or all seven of the threonine residues selected from the group consisting of Thr311, Thr313, Thr76, Thr225, Thr286, Thr391 and Thr40.

[0094] The possible combinations of phosphorylated threonine residues of dog E2F4 with Uniprot database accession number J9NSJ4 have been described above in relation to the methods of the invention and are likewise applicable to this aspect.

[0095] In another embodiment of the use of E2F4 or a functionally equivalent variant thereof, wherein the E2F4 or variant is phosphorylated in threonine as a marker of the risk of developing Alzheimer’s disease or a cognitive disorder similar to Alzheimer’s disease, the E2F4 is dog E2F4 with Uniprot database accession number F1P6Y0 and is phosphorylated in the threonine selected from the group consisting of threonine in position 251 (Thr251), threonine in position 253 (Thr253), threonine in position 14 (Thr14), threonine in position 165 (Thr165), threonine in position 226 (Thr226), threonine in position 332 (Thr332) and threonine in position 241 (Thr241), and combinations thereof, and the cognitive disorder similar to Alzheimer’s disease is cognitive dysfunction syndrome.

[0096] In another more particular embodiment, the E2F4 is dog E2F4 with Uniprot database accession number F1P6Y0 and is phosphorylated in one, two, three, four, five or all seven of the threonine residues selected from the group consisting of Thr251, Thr253, Thr14, Thr165, Thr226, Thr332 and Thr241.

[0097] The possible combinations of phosphorylated threonine residues of dog E2F4 with Uniprot database accession number F1P6Y0 have been described above in relation to the methods of the invention and are likewise applicable to this aspect.

[0098] The terms described above are likewise applicable to this aspect.

Kit of the invention

[0099] In another aspect, the invention relates to a kit comprising a reagent capable of determining the level of phosphorylation in threonine residues of E2F4 protein for determining the risk of a subject developing Alzheimer’s or a cognitive disorder similar to Alzheimer’s disease, for designing a personalized therapy in a subject or for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer’s disease or a cognitive disorder similar to Alzheimer’s disease.

[0100] As it is used herein, “kit” refers to a product containing the different reagents required for carrying out the methods of the invention packaged so as to allow their transport and storage. Materials suitable for packaging the components of the kit include glass, plastic (polyethylene, polypropylene, polycarbonate and the like), bottles, vials, paper, sachets and the like. Additionally, the kits of the invention can contain instructions for the simultaneous, sequential or separate use of the different components in the kit. Said instructions can be found in the form of a printed material or in the form of an electronic support capable of storing instructions such that they can be read by a subject, such as electronic storage media (magnetic discs, tapes and the like), optical media (CD-ROM, DVD) and the like. Additionally or alternatively, the media can contain internet addresses which provide said instructions.

[0101] As it is used herein, “reagent capable of determining the level of phosphorylation” is understood to be a compound capable of detecting a phosphorylated residue of a protein.

[0102] In a particular embodiment, the reagent capable of determining the level of phosphorylation of E2F4 protein is selected from the group consisting of:

a) a reagent capable of determining the level of phosphorylation in the threonine residue in position 248 (Thr248) of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,

b) a reagent capable of determining the level of phosphorylation in position 250 (Thr250) of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,

c) a reagent capable of determining the level of phosphorylation in the threonine residue in position 14 (Thr14) of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,

d) a reagent capable of determining the level of phosphorylation in the threonine residue in position 163 (Thr163) of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,

e) a reagent capable of determining the level of phosphorylation in the threonine residue in position 224 (Thr224) of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,

f) a reagent capable of determining the level of phosphorylation in the threonine residue in position 333 (Thr333) of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment.
alignment,
g) a reagent capable of determining the level of phosphorylation in Thr of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
h) a reagent capable of determining the level of phosphorylation in the threonine residue in position 311 (Thr311) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
i) a reagent capable of determining the level of phosphorylation in the threonine residue in position 313 (Thr313) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
j) a reagent capable of determining the level of phosphorylation in the threonine residue in position 76 (Thr76) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
k) a reagent capable of determining the level of phosphorylation in the threonine residue in position 225 (Thr225) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
l) a reagent capable of determining the level of phosphorylation in the threonine residue in position 286 (Thr286) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
m) a reagent capable of determining the level of phosphorylation in the threonine residue in position 391 (Thr391) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
n) a reagent capable of determining the level of phosphorylation in the threonine residue in position 40 (Thr40) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
o) a reagent capable of determining the level of phosphorylation in Thr in dog E2F4 protein with Uniprot database accession number J9NSJ4, or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment.
[0103] In a particular embodiment, the reagent capable of determining the level of phosphorylation of E2F4 protein is selected from the group consisting of

a) a reagent capable of determining the level of phosphorylation in the threonine residue in position 251 (Thr251) of dog E2F4 protein with Uniprot database accession number F1P6Y0 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
b) a reagent capable of determining the level of phosphorylation in the threonine residue in position 253 (Thr253) of dog E2F4 protein with Uniprot database accession number F1P6Y0 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
c) a reagent capable of determining the level of phosphorylation in the threonine residue in position 14 (Thr14) of dog E2F4 protein with Uniprot database accession number F1P6Y0 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
d) a reagent capable of determining the level of phosphorylation in the threonine residue in position 165 (Thr165) of dog E2F4 protein with Uniprot database accession number F1P6Y0 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
e) a reagent capable of determining the level of phosphorylation in the threonine residue in position 226 (Thr226) of dog E2F4 protein with Uniprot database accession number F1P6Y0 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
f) a reagent capable of determining the level of phos-
phorylation in the threonine residue in position 332 (Thr332) of dog E2F4 protein with Uniprot database accession number F1P6Y0 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment.

g) a reagent capable of determining the level of phosphorylation in the threonine residue in position 241 (Thr241) of dog E2F4 protein with Uniprot database accession number F1P6Y0 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment.

h) a reagent capable of determining the level of phosphorylation in Thr in dog E2F4 protein with Uniprot database accession number F1P6Y0, or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment.

[0104] More particularly, the reagent capable of determining the level of phosphorylation in the threonine residue in position 248 (Thr248) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 248, and wherein said Thr residue is phosphorylated.

[0105] In another particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 250 (Thr250) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 250, and wherein said Thr residue is phosphorylated.

[0106] In another particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 14 (Thr14) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 14, and wherein said Thr residue is phosphorylated.

[0107] In another particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 163 (Thr163) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 163, and wherein said Thr residue is phosphorylated.

[0108] In another particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 224 (Thr224) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 224, and wherein said Thr residue is phosphorylated.

[0109] In another particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 333 (Thr333) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 333, and wherein said Thr residue is phosphorylated.

[0110] In another particular embodiment, the reagent capable of determining the level of phosphorylation in Thr of human E2F4 protein is an anti-phosphothreonine antibody.

[0111] In another particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 311 (Thr311) of dog E2F4 protein with Uniprot database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 311, and wherein said Thr residue is phosphorylated.

[0112] In another particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 313 (Thr313) of dog E2F4 protein with Uniprot database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 313, and wherein said Thr residue is phosphorylated.

[0113] In another particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 76 (Thr76) of dog E2F4 protein with Uniprot database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 76, and wherein said Thr residue is phosphorylated.

[0114] In another particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 225 (Thr225) of dog E2F4 protein with Uniprot database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 225, and wherein said Thr residue is phosphorylated.

[0115] In another particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 286 (Thr286) of dog E2F4 protein with Uniprot database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 286, and wherein said Thr residue is phosphorylated.

[0116] In another particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 391 (Thr391) of dog E2F4 protein with Uniprot database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 391, and wherein said Thr residue is phosphorylated.
phosphorylated.

[0117] In another more particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 40 (Thr40) of dog E2F4 protein with Uniprot database accession number J9NS4J is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 40, and wherein said Thr residue is phosphorylated.

[0118] In another more particular embodiment, the reagent capable of determining the level of phosphorylation in Thr of dog E2F4 protein is an anti-phosphothreonine antibody.

[0119] In another more particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 251 (Thr251) of dog E2F4 protein with Uniprot database accession number F1P6Y0 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 251, and wherein said Thr residue is phosphorylated.

[0120] In another more particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 253 (Thr253) of dog E2F4 protein with Uniprot database accession number F1P6Y0 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 253, and wherein said Thr residue is phosphorylated.

[0121] In another more particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 14 (Thr14) of dog E2F4 protein with Uniprot database accession number F1P6Y0 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 14, and wherein said Thr residue is phosphorylated.

[0122] In another more particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 165 (Thr165) of dog E2F4 protein with Uniprot database accession number F1P6Y0 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 165, and wherein said Thr residue is phosphorylated.

[0123] In another more particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 226 (Thr226) of dog E2F4 protein with Uniprot database accession number F1P6Y0 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 226, and wherein said Thr residue is phosphorylated.

[0124] In another more particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 332 (Thr332) of dog E2F4 protein with Uniprot database accession number F1P6Y0 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 332, and wherein said Thr residue is phosphorylated.

[0125] In another more particular embodiment, the reagent capable of determining the level of phosphorylation in the threonine residue in position 241 (Thr241) of dog E2F4 protein with Uniprot database accession number F1P6Y0 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence which comprises position 241, and wherein said Thr residue is phosphorylated.

[0126] In another embodiment, the kit of the invention comprises one or more reagents mentioned above.

[0127] Additionally, the kit of the invention comprises a reagent which is capable of binding specifically to E2F4 protein. In a more particular embodiment, said reagent is an antibody.

[0128] As it is used herein, "specific recognition or specific binding," when referring to a peptide or protein with a phosphorylated residue, refers to the fact that said reagent only recognizes the peptide or protein when it is phosphorylated in the residue of interest and does not exhibit any reaction when it is not phosphorylated. When referring to a peptide or protein irrespective of its level of phosphorylation, it refers to the fact that the reagent is capable of reacting with at least one epitope of the peptide or protein, in contrast with a non-specific interaction.

[0129] As it is used herein, the term "antibody" can be a natural polyclonal or monoclonal antibody or a non-natural antibody, for example, a single-domain antibody, a single-chain variable-fragment antibody, a microantibody, etc. Methods for producing such antibodies are well known in the art.

[0130] In some embodiments, the specific antibodies used in the invention are labeled with a detectable marker (for example, a fluorescent dye or a detectable enzyme), or modified to make detection easier (for example, with biotin to allow for detection with avidin or streptavidin). In other embodiments, the reagent will not be directly labeled or modified.

[0131] In certain embodiments, the kits include the reagents in the form of an array. The array includes at least two different reagents suitable for determining the levels of phosphorylation in one or more residues of interest bound to a substrate in a predetermined pattern (for example, a grid). The present invention therefore provides arrays comprising the reagents suitable for determining the levels of phosphorylation of one or more amino acid residues mentioned in the invention.

[0132] The placement of the different reagents (the "capture reagents") allows measuring the levels of phosphorylation of a number of different amino acid residues in the same reaction. Kits including reagents in array form are usually found in sandwich format, so such kits can also contain detection reagents. Different detection reagents are usually included in the kit, where each detection reagent is specific for a different antibody. The detection reagents in such embodiments are usually reagents spe-
cific for the same proteins as the reagents bound to the substrate (although the detection reagents typically bind to a different portion or in the protein site of the substrate-bound reagents), and are generally affinity-type detection reagents. Like the detection reagents of any other assay format, the detection reagents can be modified with a detectable residue, modified to allow the separate binding of a detectable residue, or they may not be modified. Array-type kits including detection reagents which are modified or not modified to allow the binding of a detectable residue can also contain additional detectable residues (for example, detectable residues that bind to the detection reagent, such as labeled antibodies binding without modifying detection reagents or streptavidin modified with a detectable residue for biotin detection, modified detection reagents).

[0133] The antibodies can be brought about by means of methods known in the art. For example, a mammal such as a mouse, a hamster or a rabbit can be immunized with an immunogenic form of an E2F4 protein phosphorylated in a specific threonine residue (for example, antigenic fragment which can bring about an antibody response, for example a synthetic peptide containing the phosphorylated amino acid). Techniques for conferring immunogenicity to a protein or peptide include vehicle conjugation or other techniques that are very well known in the art. For example, a peptides portion of a polypeptide can be administered in the presence of an adjuvant. The progression of immunization can be monitored by detecting plasma or serum antibody titers. Standard ELISA or other immunoassays can be used with the immunogen as an antigen for evaluating the levels of antibodies.

[0134] After immunization, antisera that are reactive with a polypeptide can be obtained, and polyclonal antibodies can be isolated from the serum if desired. To produce monoclonal antibodies, antibody-producing cells (lymphocytes) can be collected from an immunized animal and fused using standard methods for fusing somatic cells with immortalizing cells, such as myeloma cells, to give rise to hybridoma cells. Such techniques are very well known in the art and include, for example, the hybridoma technique, such as the human B-cell hybridoma technique and the EVB hybridoma technique for producing human monoclonal antibodies. Hybridoma cells can be immunochemically screened for producing antibodies that are specifically reactive with the polypeptides and isolated monoclonal antibodies.

[0135] In another more particular embodiment, the reagent which is capable of binding specifically to E2F4 protein is immobilized on a support.

[0136] The terms described above are likewise applicable to this aspect.

Use of the kits of the invention

[0137] In another aspect, the invention relates to the use of a kit of the invention for determining the risk of a subject developing Alzheimer’s disease or a cognitive disorder similar to said disease in a subject, for designing a personalized therapy in a subject suffering from mild cognitive impairment or for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer’s or a cognitive disorder similar to said disease.

[0138] The terms described above are likewise applicable to this aspect.

[0139] The invention is now described in detail by means of the following examples provided only to illustrate but not limit the scope of the invention.

Materials and methods

Mice

[0140] Double transgenic mice APPswxPS1delE9 (APP/PS1) [Fernandez et al., 2012 Mol. Psychiatry 17, 705-718] and control mice C57BL6/J were used.

Obtaining blood serum

[0141] The mice were anesthetized with pentobarbital (2 mg/10 g of body weight), and 0.2-0.5 ml of blood were drawn from the right ventricle of said mice by means of a hypodermic needle (25G) before they were sacrificed by decapitation. The blood samples were stored in heparin-free test tubes and incubated at 37°C for 1 hour for the purpose of obtaining blood clots. The samples were then incubated at 4°C for at least 12 hours in order to retract the blood clot. The clot was then removed taking care not to cause any red blood cell lysis, and the samples were centrifuged (4000 rpm) for 15 minutes at 4°C to remove possible coagulation residues. The supernatants (sera) were put away, frozen at -80°C for later use.

Tissue samples

[0142] Brain hippocampal of BL6/C57 mice (control) and APPswxPS1delE9 mice (APP/PS1) [Fernandez et al., 2012 Mol. Psychiatry. 17: 705-718] sacrificed on postnatal day 0 (P0) or at 2 and 5 months of age (2 m and 5 m, respectively) and kept at -80°C were used.

[0143] Human frontal and parietal cortex samples obtained from Banco de Tejidos Fundación Cien (BT-CIEN, Madrid) and Banco de Cerebros de la Región de Murcia (Hospital Virgen de la Arrixaca, Murcia) and kept at -80°C were also used. The methods for obtaining the samples have been approved by the Ethics Committee of the Instituto de Salud Carlos III and bioethics subcommittee of the Consejo Superior de Investigaciones Científicas (Madrid, Spain).

Preparing a cell nuclear suspension

[0144] 30-40 mg of human cortex or murine brain hemi-
cortex were broken up in a Dounce homogenizer with 3 ml of DNase-free phosphate-buffered saline (PBS) con-
taining 0.1% Triton X-100 (Sigma-Aldrich, T8787) (PBS-T) and cComplete mini EDTA-free protease inhibitor (Roche Applied Science, 11 836 170 001) according to the manufacturer's indications. The homogenate thus obtained was centrifuged at 4°C for 2 minutes at 200 g. The volume of the supernatant thus obtained was adjusted to 12 ml with PBS-T and centrifuged at 4°C for 4 minutes at 400 g. The pellet thus obtained was kept in ice in a total volume of 900 μl of PBS-T for 20 minutes and then gently resuspended by means of pipetting.

**Immunofluorescent labeling of the nuclear suspension**

[0145] The nuclei of the nuclear suspension were immunolabeled with the neuron-specific anti-NeuN antibody (clone A60, Millipore, mab377). A 400 μl aliquot of the nuclear suspension (see above) to which 0.5 mg/mL bovine serum albumin (BSA, Sigma-Aldrich, A4503) and 10% bovine serum (Life Technologies, 16170-086) were incorporated was incubated for 12 hours at 4°C with the primary anti-NeuN antibody at a dilution of 1:800 and secondary anti-mouse IgG-Alexa 488 at a dilution of 1:500. Another aliquot was incubated under the same conditions without the primary antibody, this aliquot constituting the negative control. After incubation with the antibodies, the sample was filtered (nylon filter with 30 μm pore), the volume thereof was adjusted to 600 μl with PBS containing propidium iodide and RNase for a final concentration of 50 μg/mL and 25 μg/mL, respectively.

**Flow cytometry**

[0146] The quantification of the percentage of 4C neurons was carried out by means of flow cytometry using a FACSaria cytometer (BD Biosciences) and its argon excitation laser (488). The emission of the propidium iodide incorporated in the DNA and the signal of fluorophore Alexa 488 associated with anti-NeuN labeling were detected with BP 530/30 and BP 616/23 emission filters, respectively. The selection of the different analyzed populations followed the method described by López-Sánchez and Frade J. Neurosci. 33: 7488-7500, 2013.

**Statistical analysis**

[0147] Cytometry analyses were performed with at least four individuals from each group in at least three replicates for mice and two replicates for humans. The statistical significance was analyzed by means of Student's t-test.

**Quantifying E2F4 and E2F4 phosphorylated in Thr by means of ELISA**

[0148] A solution of 20 μg/ml rabbit anti-E2F4 polyclonal antibody (Ref. AP09986PUS; Acris) in TBS (50 mM Tris-HCl, pH 7.5; 150 mM NaCl) was prepared. Fifty microliters of the preceding solution were added to the bottom of each well of a Microtest™ 96-well plate (Ref. 351177; Becton Dickinson). At least six wells were used for each experimental point, three of them for quantifying the relative levels of E2F4 and the remaining three for quantifying the phosphoThr-E2F4 form. In parallel, 50 μl of TBS were added to the bottom of six other wells for obtaining the background analysis value. Finally, the plate was covered with an adhesive plastic and incubated overnight at 4°C. The solutions were removed from the wells the next day, the wells were washed two times using 200 μl of TBS each time. Then, 150 μl of TBS containing 3% bovine serum albumin (blocking buffer) were added to the bottom of each well, and the plate was covered with an adhesive plastic. The plate was then incubated for at least 2 hours at room temperature. After this incubation, the solutions were removed from the wells, the wells were washed two times using 200 μl of TBS each time. Dilutions of the blood serum in blocking buffer (1/10 dilution) were then prepared, and 50 μl of each dilution were added to the bottom of the wells coated with the rabbit anti-E2F4 polyclonal antibody, as well as to the wells incubated with TBS. The plates were then covered with an adhesive plastic, where they were incubated for at least 4 hours at room temperature. After removing the serum dilutions from the wells, the wells were washed four times using 200 μl of TBS each time. A 1/1000 dilution (in blocking buffer) of the mouse anti-E2F4 monoclonal antibody, clone LLF4-2 (Ref. MABE160; Millipore), was then prepared. This solution was used for evaluating the levels of serum E2F4. Another 1/1000 dilution (in blocking buffer) of mouse anti-phosphoThr monoclonal antibody (clone 20H6.1) (Ref. 05-1923; Millipore) was also prepared. This solution was used for estimating the relative levels of serum phosphoThr-E2F4. After adding 50 μl of these solutions to the bottom of the corresponding wells (for quantifying E2F4 or phosphoThr-E2F4), the plates were covered with an adhesive plastic and incubated overnight at 4°C. After this period elapsed, the solutions were removed from the wells and the wells were washed four times using 200 μl of TBS. A 1/2000 dilution (in blocking buffer) of goat anti-mouse IgG (H + L)-HRP conjugate (Ref. 170-6516; BioRad) was then prepared, and 50 μl of this solution were added to the bottom of each and every one of the analysis wells. The plate was then covered with an adhesive plastic and incubated for at least 2 hours at room temperature. The solutions were then removed from the wells and the wells were washed eight times using 200 μl of TBS. An ABTS tablet (Ref. 11 112 422 001; Roche) was then dissolved in 50 ml of ABTS buffer (Ref. 11 112 597 001; Roche), and 150 μl of this solution were added to the bottom of each and every one of the analysis wells, as well as to three untreated wells for estimating the value of the blank. The plate was then incubated for about 15-45 minutes at room temperature and optical density at 405 nm was quantified in the different wells using an ELISA reader. After subtracting the blank, the values obtained in the wells treated
with rabbit anti-E2F4 polyclonal antibody were deducted from those obtained in the wells initially incubated with TBS. The phosphoThr-E2F4 values thus obtained were finally divided by the values obtained for E2F4.

Example 1. Analysis of the levels of phosphorylation in Thr residues of blood serum E2F4 of APP/PS1 mice

[0149] The brain of Alzheimer's patients undergoes a tetraploidization process similar to that which occurs naturally in neurons during embryonic development and precedes the neuropathological damages defining the pathology (Figure 1).

[0150] When studying the cerebral cortex of transgenic mice APP/PS1, it is observed that the cerebral cortex of these mice shows a significant increase in the levels of phosphorylation in Thr residues of E2F4 when compared to control mice (Figure 2). This phenomenon is already observed in eight-week old mice, i.e., long before β-amyloid peptide accumulations and other neuropathological alterations in this murine line, which take place starting from 3.5 months of age, are detected (Zhang et al., 2012 Neurobiol. Aging 33: 2661-2677). Furthermore, this increase in phosphorylation is concomitant with the neuronal tetraploidization process observed in the cerebral cortex of these mice (Figure 3). Therefore, phosphorylation of E2F4 and neuronal tetraploidization would be the earliest events known, prior to AD.

[0151] It can be observed how the levels of phosphoThr-E2F4 increase significantly in the serum of 2-month old APP/PS1 mice (Figure 4A), right when neuronal tetraploidy is observed to increase substantially (Figure 3). In contrast, the levels of phosphoThr-E2F4 decrease significantly in the serum of APP/PS1 mice when these mice are 5 months old (Figure 4B), and the tetraploidization process is greatly reduced (Figure 3).

[0152] Therefore, the increase in the levels of E2F4 phosphorylated in Thr in samples from a patient can be used for the diagnosis of AD (Alzheimer's disease). Furthermore, given that the increase in the levels of E2F4 phosphorylated in Thr occurs at a time point of the disease before the onset of symptoms, this marker can be used for prognostic purposes in order to determine the risk of a subject developing Alzheimer's disease. This can furthermore be carried out in a minimally invasive manner given that the levels of E2F4 phosphorylated in Thr can be detected in plasma and peripheral tissues.

Claims

1. An in vitro method for determining the risk of developing Alzheimer's disease or a cognitive disorder similar to said disease in a subject, which method comprises

   a) determining in a sample from the subject the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant and
   b) comparing the level of phosphorylation obtained in a) to a reference value,

   wherein an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to a reference value is indicative that said subject has a high risk of developing Alzheimer's or a cognitive disorder similar to said disease.

2. The method according to claim 1, wherein the subject suffers from mild cognitive impairment.

3. The method according to claim 1 or 2, wherein the subject is a human and the neurodegenerative disease is Alzheimer's disease, or wherein the subject is a dog and the cognitive disorder similar to Alzheimer's disease is cognitive dysfunction syndrome.

4. An in vitro method for designing a personalized therapy in a subject suffering from mild cognitive impairment, which method comprises

   a) determining in a sample from the subject the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant and
   b) comparing the level of phosphorylation obtained in a) to a reference value,

   wherein an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to a reference value is indicative that said subject is susceptible to receive a therapy for the prevention and/or treatment of Alzheimer's disease or a cognitive disorder similar to said disease.

5. The method according to claim 4, wherein the subject is a human and the therapy is for the prevention and/or treatment of Alzheimer's disease, or wherein the subject is a dog and the therapy is for the prevention and/or treatment of cognitive dysfunction syndrome.

6. An in vitro method for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer's or a cognitive disorder similar to said disease, which method comprises

   a) determining in a sample from the subject the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant and
   b) comparing the level of phosphorylation obtained in a) to a reference value,
wherein an increase in the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant compared to the reference value is indicative that said subject is a candidate for receiving a therapy for the prevention and/or treatment of Alzheimer’s disease or a cognitive disorder similar to said disease.

7. The method according to claim 6, wherein the subject is a human and the therapy is for the prevention and/or treatment of Alzheimer’s disease, or wherein the subject is a dog and the therapy is for the prevention and/or treatment of cognitive dysfunction syndrome.

8. The method according to any of claims 1 to 7, wherein determining the level of phosphorylation in threonine residues in E2F4 protein comprises determining the phosphorylation of the threonine residue selected from the group consisting of threonine residue in position 248 (Thr248), threonine residue in position 250 (Thr250), threonine residue in position 14 (Thr14), threonine residue in position 163 (Thr163), threonine residue in position 224 (Thr224) and threonine residue in position 333 (Thr333), and combinations thereof, of human E2F4 protein, or in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment or in a functionally equivalent variant.

9. The method according to any of claims 1 to 7, wherein the subject is a dog and wherein the phosphorylation of the threonine residue selected from the group consisting of threonine residue in position 311 (Thr311), threonine residue in position 313 (Thr313), threonine residue in position 76 (Thr76), threonine residue in position 225 (Thr225), threonine residue in position 286 (Thr286), threonine residue in position 391 (Thr391), threonine residue in position 40 (Thr40) and combinations thereof of dog E2F4 protein with Uniprot database accession number J9NSJ4, or of a functionally equivalent variant, is determined.

10. The method according to any of claims 1 to 9, wherein the sample is selected from the group of cerebrospinal fluid, blood serum, blood plasma, blood and peripheral blood mononuclear cells.

11. The method according to any of claims 1 to 10, wherein the level of phosphorylation is determined by means of ELISA.

12. Use of E2F4 or a functionally equivalent variant thereof, wherein the E2F4 or variant is phosphorylated in threonine as a marker of the risk of developing Alzheimer’s disease or a cognitive disorder similar to Alzheimer’s disease.

13. Use according to claim 12, wherein the E2F4 is of human origin and is phosphorylated in the threonine selected from the group consisting of threonine in position 248 (Thr248), threonine in position 250 (Thr250), threonine in position 14 (Thr14), threonine in position 163 (Thr163), threonine in position 224 (Thr224), threonine in position 333 (Thr333) and combinations thereof, and the disease is Alzheimer’s disease.

14. Use according to claim 12, wherein the E2F4 is dog E2F4 with Uniprot database accession number J9NSJ4 and is phosphorylated in the threonine selected from the group consisting of threonine in position 311 (Thr311), threonine in position 313 (Thr313), threonine in position 76 (Thr76), threonine in position 225 (Thr225), threonine in position 286 (Thr286), threonine in position 391 (Thr391), threonine in position 40 (Thr40) and combinations thereof, and the cognitive disorder similar to Alzheimer’s disease is cognitive dysfunction syndrome.

15. A kit comprising a reagent capable of determining the level of phosphorylation in threonine residues of E2F4 protein.

16. The kit according to claim 15, wherein the reagent capable of determining the level of E2F4 protein phosphorylation is selected from the group consisting of

a) a reagent capable of determining the level of phosphorylation in the threonine residue in position 248 (Thr248) of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,

b) a reagent capable of determining the level of phosphorylation in position 250 (Thr250) of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,

c) a reagent capable of determining the level of phosphorylation in the threonine residue in position 14 (Thr14) of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,

d) a reagent capable of determining the level of phosphorylation in the threonine residue in position 163 (Thr163) of human E2F4 protein or of a functionally equivalent variant in a phosphor-
ylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
e) a reagent capable of determining the level of phosphorylation in the threonine residue in position 224 (Thr224) of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
f) a reagent capable of determining the level of phosphorylation in the threonine residue in position 333 (Thr333) of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
g) a reagent capable of determining the level of phosphorylation in Thr of human E2F4 protein or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
h) a reagent capable of determining the level of phosphorylation in the threonine residue in position 311 (Thr311) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
i) a reagent capable of determining the level of phosphorylation in the threonine residue in position 313 (Thr313) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
j) a reagent capable of determining the level of phosphorylation in the threonine residue in position 76 (Thr76) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
k) a reagent capable of determining the level of phosphorylation in the threonine residue in position 225 (Thr225) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
l) a reagent capable of determining the level of phosphorylation in the threonine residue in position 286 (Thr286) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
m) a reagent capable of determining the level of phosphorylation in the threonine residue in position 391 (Thr391) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
n) a reagent capable of determining the level of phosphorylation in the threonine residue in position 40 (Thr40) of dog E2F4 protein with Uniprot database accession number J9NSJ4 or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment,
o) a reagent capable of determining the level of phosphorylation in Thr in dog E2F4 protein, or of a functionally equivalent variant in a phosphorylatable, positionally equivalent amino acid residue of another E2F4 protein as defined by multiple amino acid sequence alignment.

17. The kit according to claim 16, wherein:

a) the reagent capable of determining the level of phosphorylation in the threonine residue in position 248 (Thr248) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 248, and wherein said Thr residue is phosphorylated,
b) the reagent capable of determining the level of phosphorylation in the threonine residue in position 250 (Thr250) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 250, and wherein said Thr residue is phosphorylated,
c) the reagent capable of determining the level of phosphorylation in the threonine residue in position 14 (Thr14) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 14, and wherein said Thr residue is phosphorylated,
d) the reagent capable of determining the level of phosphorylation in the threonine residue in position 163 (Thr163) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 163, and wherein said Thr residue is phosphorylated,
e) the reagent capable of determining the level of phosphorylation in the threonine residue in position 224 (Thr224) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 224, and wherein said Thr residue is phosphorylated,
f) the reagent capable of determining the level of phosphorylation in the threonine residue in position 333 (Thr333) of human E2F4 protein is an antibody specifically recognizing a phosphopeptide comprising the human E2F4 sequence which comprises position 333, and wherein said Thr residue is phosphorylated,
g) the reagent capable of determining the level of phosphorylation in Thr of human E2F4 protein is an anti-phosphothreonine antibody,
h) the reagent capable of determining the level of phosphorylation in the threonine residue in position 311 (Thr311) of dog E2F4 protein with UniProt database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence with UniProt database accession number J9NSJ4 which comprises position 311, and wherein said Thr residue is phosphorylated,
i) the reagent capable of determining the level of phosphorylation in the threonine residue in position 313 (Thr313) of dog E2F4 protein with UniProt database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence with UniProt database accession number J9NSJ4 which comprises position 313, and wherein said Thr residue is phosphorylated,
j) the reagent capable of determining the level of phosphorylation in the threonine residue in position 76 (Thr76) of dog E2F4 protein with UniProt database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence with UniProt database accession number J9NSJ4 which comprises position 76, and wherein said Thr residue is phosphorylated,
k) the reagent capable of determining the level of phosphorylation in the threonine residue in position 225 (Thr225) of dog E2F4 protein with UniProt database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence with UniProt database accession number J9NSJ4 which comprises position 225, and wherein said Thr residue is phosphorylated,
l) the reagent capable of determining the level of phosphorylation in the threonine residue in position 286 (Thr286) of dog E2F4 protein with UniProt database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence with UniProt database accession number J9NSJ4 which comprises position 286, and wherein said Thr residue is phosphorylated,
m) the reagent capable of determining the level of phosphorylation in the threonine residue in position 391 (Thr391) of dog E2F4 protein with UniProt database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence with UniProt database accession number J9NSJ4 which comprises position 391, and wherein said Thr residue is phosphorylated,
n) the reagent capable of determining the level of phosphorylation in the threonine residue in position 40 (Thr40) of dog E2F4 protein with UniProt database accession number J9NSJ4 is an antibody specifically recognizing a phosphopeptide comprising the dog E2F4 sequence with UniProt database accession number J9NSJ4 which comprises position 40, and wherein said Thr residue is phosphorylated,
o) the reagent capable of determining the level of phosphorylation in Thr of dog E2F4 protein is an anti-phosphothreonine antibody.

18. The kit according to any of claims 15 to 17, additionally comprising a reagent which is capable of binding specifically to E2F4 protein.

19. The kit according to claim 18, wherein the reagent which is capable of binding specifically to E2F4 protein is an antibody.

20. The kit according to claim 18 or 19, wherein the reagent which is capable of binding specifically to E2F4 protein is immobilized on a support.

21. Use of the kit according to any of claims 15 to 20 for determining the risk of a subject developing Alzheimer's disease or a cognitive disorder similar to said disease in a subject, for designing a personalized therapy in a subject suffering from mild cognitive impairment or for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer's or a cognitive disorder similar to said disease.
Fig. 1
Fig. 2
Fig. 3
Fig. 4
## INTERNATIONAL SEARCH REPORT

International application No.
PCT/ES2016/070485

### A. CLASSIFICATION OF SUBJECT MATTER

G01N33/53 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

INVENES, EPODOC, WPI, NPL, BIOSIS, MEDLINE, EMBASE, PUBMED, USPTO PATENT DATABASE, GOOGLE PATENTS.

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 2013076331 A1 (CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, CSIC [ES/ES]) 30.05.2013, page 3, line 21 – page 4, line 2; claims 1, 11-13.</td>
<td>1-7, 10-12, 15, 18-21</td>
</tr>
<tr>
<td>A</td>
<td>ES 2325350 T1 (BLANCHETT ROCKEFELLER NEUROSCIENCES INSTITUTE) 02.09.2009, claim 1.</td>
<td>1-7, 10-12, 15, 18-21</td>
</tr>
</tbody>
</table>

Further documents listed in the continuation of Box C. See patent family annex.

4 Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance.
- "E" earlier document but published on or after the international filing date.
- "L" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.
- "X" document published prior to the international filing date but later than the priority date claimed.
- "O" document referring to an oral disclosure, exhibition, or other means.
- "P" document published prior to the international filing date but later than the priority date claimed.

Date of the actual completion of the international search: 31/08/2016

Date of mailing this international search report: (01/09/2016)

Name and mailing address of the ISA:

**OFFICINA ESPAÑOLA DE PATENTES Y MARCAS**

Paseo de la Castellana, 75 - 28071 Madrid (España)

Facsimile No.: 91 349 53 04

Authorized officer: M. García Grávidas

Telephone No. 91 349 34 04

Form PCT/ISA/210 (second sheet) (January 2015)
INTERNATIONAL SEARCH REPORT

Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  □ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2.  □ Claims Nos.  8, 9, 13, 14, 16, 17
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3.  □ Claims Nos.
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  □ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2.  □ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3.  □ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4.  □ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest  □ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
□ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
□ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2015)
<table>
<thead>
<tr>
<th>Patent document cited in the search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO2013076331 A1</td>
<td>30.05.2013</td>
<td>US2015018278 A1</td>
<td>15.01.2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES2409779 A1</td>
<td>27.06.2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP2783696 A1</td>
<td>01.10.2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP2783696 A4</td>
<td>01.07.2015</td>
</tr>
<tr>
<td>ES2325350T T1</td>
<td>02.09.2009</td>
<td>KR2004086145 A</td>
<td>08.10.2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR100941597B B1</td>
<td>11.02.2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP2013078330 A</td>
<td>02.05.2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US2010278803 A</td>
<td>04.11.2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US9188595 B2</td>
<td>17.11.2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP2009148247 A</td>
<td>09.07.2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE08002964T T1</td>
<td>03.09.2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR100902568B B1</td>
<td>01.06.2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES2305234T T3</td>
<td>01.11.2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US2005059992 A</td>
<td>17.03.2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US6782807 B2</td>
<td>23.03.2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO02067764 A2</td>
<td>06.09.2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO20067764 A3</td>
<td>14.11.2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP2004533218 A</td>
<td>04.11.2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP1925315 A2</td>
<td>28.05.2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP1925315 A3</td>
<td>18.11.2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP1385531 A2</td>
<td>04.02.2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP1385531 A4</td>
<td>12.05.2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN1549721 A</td>
<td>24.11.2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN1549721B B</td>
<td>07.03.2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU2002254029 A1</td>
<td>12.09.2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT394115T T</td>
<td>15.05.2008</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (patent family annex) (January 2015)
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- ALTSCHUL, S. BLAST Manual. NCBI NLM NIH, 20894 [0038]